Back to Search
Start Over
Medical Complications of Psychoactive Substances with Abuse Risks: Detection and Assessment by the Network of French Addictovigilance Centres
- Source :
- Therapie, Therapie, 2016, 71 (6), pp.563-573. ⟨10.1016/j.therap.2016.07.001⟩
- Publication Year :
- 2016
- Publisher :
- HAL CCSD, 2016.
-
Abstract
- International audience; The use of psychoactive substances, whether occasional or regular, can induce a large number of clinical and/or biological complications. These complications may be related to the effects of the active substance itself and/or adulterants, but also to the modalities for use (administrations route, contexts of use). The detection and evaluation of these potentially severe complications are a public health issue. Beyond the assessment of the potential for abuse of and dependence on psychoactive substances, the collection and evaluation of complications related to the use of the substances are one of the roles of addictovigilance centres. In this article, the expertise of the French addictovigilance centres in the detection and assessment of medical complications related to psychoactive substances, adulterants or route of administration of substances is advanced through a few recent examples.
- Subjects :
- medicine.medical_specialty
Surveillance de la santé publique
Modalities
Public heath surveillance
Complications
Abus de drogue
business.industry
Public health
[SDV]Life Sciences [q-bio]
medicine.disease
030226 pharmacology & pharmacy
Drug abuse
3. Good health
Substance abuse
03 medical and health sciences
0302 clinical medicine
medicine
Pharmacology (medical)
Troubles liés à l’usage de substances
030212 general & internal medicine
Psychiatry
business
Intensive care medicine
Substance-related disorders
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Therapie, Therapie, 2016, 71 (6), pp.563-573. ⟨10.1016/j.therap.2016.07.001⟩
- Accession number :
- edsair.doi.dedup.....e7fff82297af97f626f924dd5e2bf0ca
- Full Text :
- https://doi.org/10.1016/j.therap.2016.07.001⟩